Chemical Namemobocertinib
Dosage FormCapsule (oral; 40 mg)
Drug ClassKinase inhibitors
Approval Year2021


  • For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy
Last updated on 3/15/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Exkivity (mobocertinib) Prescribing Information.2021Takeda Pharmaceuticals America Inc., Lexington, MA